FDA Approves New Antibiotic for Three Different Uses

  05 April 2024

The U.S. Food and Drug Administration has approved Zevtera for treating adults with Staphylococcus aureus bloodstream infections (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). The FDA is committed to promoting new antibiotic availability when they prove safe and effective. Zevtera’s efficacy was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial, with 69.8% of subjects achieving overall success compared to 68.7% of subjects receiving the comparator.

Further reading: FDA
Author(s): FDA
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed